These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29307568)

  • 1. A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design.
    Morfouace M; Hewitt SM; Salgado R; Hartmann K; Litiere S; Tejpar S; Golfinopoulos V; Lively T; Thurin M; Conley B; Lacombe D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):158-165. PubMed ID: 29307568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting.
    Vermaelen K; Waeytens A; Kholmanskikh O; Van den Bulcke M; Van Valckenborgh E
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):166-177. PubMed ID: 29170067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.
    Peskov K; Azarov I; Chu L; Voronova V; Kosinsky Y; Helmlinger G
    Front Immunol; 2019; 10():924. PubMed ID: 31134058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.
    Butterfield LH; Disis ML; Fox BA; Kaufman DR; Khleif SN; Wang E;
    J Immunother Cancer; 2018 Dec; 6(1):138. PubMed ID: 30514399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer genomics and immuno-oncological markers to guide immune therapies.
    Hammerl D; Smid M; Timmermans AM; Sleijfer S; Martens JWM; Debets R
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):178-188. PubMed ID: 29104025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candidate immune biomarkers for radioimmunotherapy.
    Levy A; Nigro G; Sansonetti PJ; Deutsch E
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):58-68. PubMed ID: 28254528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating Immuno-oncology Biomarkers to Diagnostic Tests: A Regulatory Perspective.
    Li Y; Veeraraghavan J; Philip R
    Methods Mol Biol; 2020; 2055():701-716. PubMed ID: 31502175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What, Why, Where, and When: Bringing Timing to Immuno-Oncology.
    Rothschilds AM; Wittrup KD
    Trends Immunol; 2019 Jan; 40(1):12-21. PubMed ID: 30545676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
    Maio M; Coukos G; Ferrone S; Fox BA; Fridman WH; Garcia PL; Lahn M; Provendier O; Russo V; Rüttinger D; Shalabi A; Trajanoski Z; Viallet J; Wolchok JD; Ibrahim R
    Cancer Immunol Immunother; 2019 Jan; 68(1):1-9. PubMed ID: 30564889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
    Nicolini A; Ferrari P; Duffy MJ
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.
    Baik CS; Rubin EH; Forde PM; Mehnert JM; Collyar D; Butler MO; Dixon EL; Chow LQM
    Clin Cancer Res; 2017 Sep; 23(17):4992-5002. PubMed ID: 28864727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-Oncology in the Era of Personalized Medicine.
    Gwin WR; Disis ML; Ruiz-Garcia E
    Adv Exp Med Biol; 2019; 1168():117-129. PubMed ID: 31713168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
    Anagnostou V; Yarchoan M; Hansen AR; Wang H; Verde F; Sharon E; Collyar D; Chow LQM; Forde PM
    Clin Cancer Res; 2017 Sep; 23(17):4959-4969. PubMed ID: 28864724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging targets in cancer immunotherapy.
    Burugu S; Dancsok AR; Nielsen TO
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.
    Giraldo NA; Peske JD; Sautès-Fridman C; Fridman WH
    Virchows Arch; 2019 Apr; 474(4):463-474. PubMed ID: 30631935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for checkpoint inhibition in hematologic malignancies.
    Atanackovic D; Luetkens T
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies.
    Slovin SF
    Biomark Med; 2017 Dec; 11(12):1149-1159. PubMed ID: 29186979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for Immunotherapy: Current Developments and Challenges.
    Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.